Login to Your Account



3SBio inks licensing deal with Korea's Dinona for leukemia candidate

By Cornelia Zou
Staff Writer

Friday, August 8, 2014

3SBio Inc. has entered an exclusive licensing agreement with Korean biotech Dinona Inc. for 3SBio to develop, manufacture and market leukotuximab in Greater China to offer better treatment to Chinese leukemia patients and reinforce its blood-related disorders pipeline.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription